Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...

Detailed price information for Foghorn Therapeutics Inc (FHTX-Q) from The Globe and Mail including charting and trades.

HIV franchise still drives growth, oncology M&A faces skepticism, & valuation looks cheap at ~16x P/E. Click for this GILD ...

Jade Biosciences is a pre-revenue biotech focused on JADE101 for IgA nephropathy, offering potential. Read why I rate JBIO ...

Bile Acid Medicines Sales -- $41 million attributed to CHOLBAM and CTEXLI medicines supported by expanded CTX patient finding after CTEXLI's FDA approval. Japan Partner Sales -- $5 million recognized ...

Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

By Ben TAGOEThe Security-Productivity ChallengeEvery business faces a fundamental tension: security measures designed to protect the organization often slow down the very workflows that drive growth ...

In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...

Biomarkers are revolutionizing oncology drug development, driving modern precision medicine approaches, targeted clinical trial recruitment strategies, and critical decision-making.

This growth is fueled by advancements in early diagnostics, a rising incidence of liver and bile duct disorders, and the expansion ...